Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Plus ADT and Abiraterone in Newly Diagnosed mHSPC
NCT04925063Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2021
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liquid metformin (Aspargo Labs) in prostate cancer (PCa) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Castration-resistant prostate cancer free survival at 5 years. Started Jun 2021; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04925063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925063.